Swiss National Bank Has $10.75 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Swiss National Bank increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 116,200 shares of the biotechnology company’s stock after buying an additional 1,800 shares during the quarter. Swiss National Bank owned about 0.18% of Blueprint Medicines worth $10,748,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Amalgamated Bank grew its holdings in shares of Blueprint Medicines by 5.3% during the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after buying an additional 109 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Blueprint Medicines by 13.3% during the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 131 shares during the last quarter. EFG Asset Management North America Corp. increased its position in Blueprint Medicines by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after buying an additional 132 shares during the last quarter. Pallas Capital Advisors LLC raised its stake in Blueprint Medicines by 3.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares during the period. Finally, Clarus Wealth Advisors lifted its stake in shares of Blueprint Medicines by 8.6% during the 3rd quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 206 shares in the last quarter.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.21% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BPMC. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Wedbush restated an “outperform” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Thursday, November 14th. Guggenheim lifted their target price on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $122.11.

Blueprint Medicines Price Performance

BPMC stock opened at $94.15 on Monday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines Co. has a 12 month low of $66.61 and a 12 month high of $121.90. The stock has a market cap of $5.98 billion, a PE ratio of -44.62 and a beta of 0.59. The company has a 50-day moving average price of $90.36 and a 200 day moving average price of $98.46.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s revenue was up 126.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.20) earnings per share. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.